These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35713182)

  • 21. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
    Wu B; Shen P; Yin X; Yu L; Wu F; Chen C; Li J; Xu T
    Br J Clin Pharmacol; 2023 Feb; 89(2):440-448. PubMed ID: 35349180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
    Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
    Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADER.
    Ohyama K; Okamoto T; Hori Y
    Int J Clin Pharmacol Ther; 2023 Jan; 61(1):16-23. PubMed ID: 36366967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
    Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
    Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
    Qian J; Truong CB; Tanni KA
    BioDrugs; 2021 May; 35(3):375-377. PubMed ID: 33860920
    [No Abstract]   [Full Text] [Related]  

  • 29. Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
    Woods RH
    Br J Clin Pharmacol; 2023 Aug; 89(8):2386-2395. PubMed ID: 36321844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
    Motola D; Piccinni C; Biagi C; Raschi E; Marra A; Marchesini G; Poluzzi E
    Drug Saf; 2012 Apr; 35(4):315-23. PubMed ID: 22376166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.
    Khadem TM; van Manen RP; Brown J
    Pharmacotherapy; 2014 Dec; 34(12):1324-9. PubMed ID: 25421400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System.
    Gupta AK; Carviel J; Gupta MA; Shear NH
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1373-1376. PubMed ID: 29194783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database.
    Papazisis G; Siafis S; Cepatyte D; Giannis D; Stamoula E; Tzachanis D; Egberts T
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(19):6003-6012. PubMed ID: 34661260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
    Caldito NG; Shirani A; Salter A; Stuve O
    Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database.
    Li H; Zhang M; Jiao X; Zhu Y; Liu Y; Zeng L; Wang H; Zhang L; Zhang W; Zhang L
    Sci Rep; 2023 Mar; 13(1):4475. PubMed ID: 36934109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vemurafenib Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Disproportionality Analysis in FAERS Database.
    Neha R; Beulah E; Anusha B; Vasista S; Stephy C; Subeesh V
    Curr Rev Clin Exp Pharmacol; 2021; 16(2):168-173. PubMed ID: 32598268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
    Ohyama K; Kawakami H; Inoue M
    Biol Pharm Bull; 2017; 40(5):616-620. PubMed ID: 28458346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.